Weaker Tumor Microenvironments, Stronger Immunotherapies
To deny cancer cells succor and sanctuary, drug developers are expanding checkpoint inhibition, assisting immune infiltration, and blocking Treg recruitment.
Omar Robles Bryan Mcclure Pravin Iyer Timothy Machajewski Glenmark Pharmaceuticals Pliant Therapeutics
Source: genengnews.com